SUV39H2 and prostate carcinoma: Additionally, SUV39H2 knockdown significantly impaired cell viability in response to docetaxel treatment compared to control cells, indicating that SUV39H2 contributes to docetaxel resistance in prostate cancer (Sun et al., 2024).